newsfilter
← Latest News
GlobeNewswire·

Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarterContinued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0